WithdrawnNot Applicable

Biomarkers in Neurodegenerative Diseases

Stopped: Lack of regulatory approval

United States0Started 2019-10-01

Plain-language summary

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of MCI, AD, DLB, FTLD, PDD, TEA, TLE, SCA, HAND, ALS, PLS, or normal control.
✓. Age 18 or older
✓. Reliable informant with frequent contact with participant
✓. Mini Mental State Exam (MMSE) ≥15 AND/OR Clinical Dementia Rating (CDR) less than 2
✓. Able to undergo extensive psychometric testing

Exclusion criteria

✕. Any conditions that could account for cognitive deficits in addition to a neurodegenerative disease, including but not limited to:
✕. Present significant systemic medical illness, such as cancer requiring chemotherapy or end stage cardiac insufficiency
✕. Present inability to safely scan in an MRI
✕. Present pregnancy or lactation - Female participants will be asked to confirm that they are not pregnant and do not plan to become pregnant.
✕. Present current medication likely to affect CNS functions:

What they're measuring

Performance on Batteries of Cognitive Tests

Timeframe: 2-5 Years

Trial details

NCT IDNCT04055532

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10-01

View on ClinicalTrials.gov More Mild Cognitive Impairment (MCI) trials